Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | CCKAR | P32238 | 5/20 | 0.41 |
| ▸ | CCKBR | P32239 | 5/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18885578 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL15369019 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL2373708 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL21242756 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL18885624 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24899308 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL22245502 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL25454272 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL22245528 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL2040679 | 1.00 | GLP1R (0.62) | GLP1RNOD1CCKARCCKBRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310616-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-11529394-B2 | Polypeptide conjugates and methods of uses | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20220133856-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20220016254-A1 | CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21 | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| WO-2021043803-A1 | PROCESS FOR PRODUCING A TABLET COMPRISING GLP-1 PEPTIDES | NOVO NORDISK A/S (DK) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529394-B2 | Polypeptide conjugates and methods of uses | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 1241/4885CCKAR 24/4885 |
| US-20230310616-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 621/4885CCKAR 15/4885 |
| US-20220133856-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 1241/4885CCKAR 24/4885 |
| US-20220016254-A1 | CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21 | GLP1R, GIPR, FGFR1 | GLP1R 1/4885NOD1 1107/4885CCKAR 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.